Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Veru's candidate, sabizabulin, appears to be both safe and effective at treating severe COVID-19. The company could get the medicine to the market very quickly if regulators give the green light. The ...

Public Offering Proceeds: Approximately $23.4 million from an offering completed on October 31, 2025. Research and Development Costs: Increased to $15.6 million in fiscal 2025 from $12.8 million in ...

Drug developer Veru Inc on Tuesday said it plans to proceed with a late-stage trial of its COVID-19 pill, weeks after the U.S. health regulator declined to authorize the oral drug to treat high-risk ...

Veru's valuation has both soared and crashed in 2022 due to its COVID-19 drug. The company recently reported underwhelming earnings numbers, which only gave investors more of a reason to be bearish on ...

The stock price of Veru Inc. (NASDAQ: VERU), a biopharmaceuticals company focused on oncology medicines, has seen a monstrous 112% rise over the last ten trading days, while it’s up 47% over the last ...

Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company’s drug development ...

Veru Inc. (NASDAQ:VERU) shares jumped on Tuesday after the company disclosed the sale of its FC2 Female Condom (Internal Condom) business to clients managed by Riva Ridge Capital Management LP and ...

Additional information on the meeting can be found on the following website: https://obesityweek.org/. About Veru Inc. Veru is a late clinical stage biopharmaceutical ...

After a stellar 3x rise since the March 23 levels of last year, at the current price of around $10 per share we believe Veru Inc. stock (NASDAQ: VERU), a biopharmaceuticals company focused on oncology ...

Veru (NASDAQ: VERU), a high-flying cancer and COVID-19 stock, is in full-on retreat mode today. Specifically, the biotech's shares were down by a hefty 17%, on average volume, as of 12:38 p.m. ET ...